In this article, Aptar Pharma uses inductively coupled plasma optical emission spectrometry (ICP-OES) to demonstrate that our proprietary manufacturing process optimizes the distribution of silicone oil on our PremiumCoat®. By limiting the quantity of silicone that comes in contact with the drug product, PremiumCoat® derisks the development of sensitive drugs.
Learn more about PremiumCoat® Platform
This Might Also Be of Interest
 
    Aptar Pharma’s Ready-to-Use Program Facilitates Development Times
Publications, Pharmaceutical, Innovation & Insights, Product Solutions
 
    Good Medicine: Solutions for Sensitive Injectable Formulations
Webinars, Pharmaceutical, Innovation & Insights, Drug Delivery Innovations, Market Insights, Product Solutions
 
    Connected Medicine: Insights from Payers and Other Stakeholders
Publications, Pharmaceutical, Innovation & Insights, Drug Delivery Innovations, Brand Differentiation, Product Solutions
 
    Pharma Partnering Considerations for Injectable Device Components
Publications, Pharmaceutical, Product Solutions, Innovation & Insights, Drug Delivery Innovations
